Edwards Lifesciences (EW) Share-based Compensation (2009 - 2026)

Edwards Lifesciences has reported Share-based Compensation for 18 years, with the latest figure at $45.4 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 12.94% year-over-year to $45.4 million; the trailing twelve-month figure through Mar 2026 stood at $163.3 million (up 3.42% YoY), and the FY2025 full-year result was $158.1 million, down 2.59% from the prior year.
• Share-based Compensation for Q1 2026 stood at $45.4 million, up from $39.2 million in the prior quarter.
• The five-year high for Share-based Compensation was $45.4 million in Q1 2026, with the low at $27.9 million in Q4 2022.
• Average Share-based Compensation over 5 years is $37.2 million, with a median of $37.5 million recorded in 2025.
• Year-over-year, Share-based Compensation increased 29.14% in 2024 and fell 14.58% in 2025.
• Tracing EW's Share-based Compensation over 5 years: stood at $27.9 million in 2022, then grew by 9.32% to $30.5 million in 2023, then grew by 3.93% to $31.7 million in 2024, then rose by 23.66% to $39.2 million in 2025, then gained by 15.82% to $45.4 million in 2026.
• The last three Share-based Compensation figures came in at $45.4 million (Q1 2026), $39.2 million (Q4 2025), and $41.2 million (Q3 2025), per Business Quant data.

Peer Comparison